Humasis Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 52.35%

Humasis Co. Ltd (205470) has an Asset Resilience Ratio of 52.35% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Humasis Co. Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

₩177.84 Billion
≈ $120.52 Million USD Cash + Short-term Investments

Total Assets

₩339.69 Billion
≈ $230.21 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Humasis Co. Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Humasis Co. Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Humasis Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Humasis Co. Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩177.84 Billion 52.35%
Total Liquid Assets ₩177.84 Billion 52.35%

Asset Resilience Insights

  • Very High Liquidity: Humasis Co. Ltd maintains exceptional liquid asset reserves at 52.35% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Humasis Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Humasis Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 3.37%
CareRay Digital Medical Technology Co Ltd
SHG:688607
Medical Devices 16.21%
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
Medical Devices 54.67%
Universus Photo Imagings Limited
NSE:UNIVPHOTO
Medical Devices 30.97%
HansBiomed Corporation
KQ:042520
Medical Devices 9.13%
Aligned Genetics Inc
KQ:238120
Medical Devices 2.22%
Heramed Ltd
AU:HMD
Medical Devices 0.83%
Acarix A/S
ST:ACARIX
Medical Devices 37.81%

Annual Asset Resilience Ratio for Humasis Co. Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Humasis Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 58.65% ₩194.68 Billion
≈ $131.93 Million
₩331.92 Billion
≈ $224.93 Million
-11.31pp
2023-12-31 69.96% ₩242.99 Billion
≈ $164.67 Million
₩347.31 Billion
≈ $235.37 Million
+1.80pp
2022-12-31 68.16% ₩318.69 Billion
≈ $215.97 Million
₩467.53 Billion
≈ $316.84 Million
+10.88pp
2021-12-31 57.29% ₩195.19 Billion
≈ $132.28 Million
₩340.71 Billion
≈ $230.90 Million
+23.65pp
2020-12-31 33.64% ₩22.99 Billion
≈ $15.58 Million
₩68.35 Billion
≈ $46.32 Million
-25.57pp
2019-12-31 59.21% ₩21.60 Billion
≈ $14.64 Million
₩36.49 Billion
≈ $24.73 Million
-1.64pp
2018-12-31 60.85% ₩20.87 Billion
≈ $14.14 Million
₩34.29 Billion
≈ $23.24 Million
+6.10pp
2017-12-31 54.75% ₩15.51 Billion
≈ $10.51 Million
₩28.32 Billion
≈ $19.19 Million
-45.03pp
2016-12-31 99.78% ₩12.10 Billion
≈ $8.20 Million
₩12.13 Billion
≈ $8.22 Million
--
pp = percentage points

About Humasis Co. Ltd

KQ:205470 Korea Medical Devices
Market Cap
$61.42 Million
₩90.64 Billion KRW
Market Cap Rank
#21077 Global
#1316 in Korea
Share Price
₩801.00
Change (1 day)
-1.72%
52-Week Range
₩682.00 - ₩1899.00
All Time High
₩8520.77
About

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more